osl's brachy option has passed in vivo testing and will...

osl's brachy option has passed in vivo testing and will inevitably achieve superior dose delivery with lower gut toxicity cf external beam radiotherapy/ cyberknife.
the main issue is not respiratory movement but gut toxicity at high effective doses which is unavoidable with any external technique even with imrt/ conformal 3D ebrt.
i prefer oncosil to the competitor but both have potential.
endoscopic ultrasound (eus) is the delivery method via stomach/ dudmodenun as it commonly done already for biopsies etc.
psma is takeb up by pancreas and salivary glands but less avidly than prostate so i havnt seen any good data for its efficacy in pancreatic ca (although i agree it is worth exploring).
i dont see any problem accessing tail of pancreas lesions or large nodes in the portahepatis/ coeliac/ sma regions (if a single large node at risk of local compression of surrounding structures).

i cant predict ce mark for sure and understand the wise scepticism of long term holders who are growing impatient, but i would have thought you would kick yourself if you sold and it popped up on approval a month or two later.

management will not have forgotten that they have not met their previous timeline predictions and they will be feeling pressure to deliver as a matter of urgency to protect their own equity and solidify the confidence of investors